Trial · NCT00010257
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
NCT00010257, Phase 2, Completed, Eastern Cooperative Oncology Group; results first posted 2012-10-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma. Trials, record NCT00010257. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00010257
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
- NCT number
- NCT00010257
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 46 participants, actual
- Lead sponsor
- Eastern Cooperative Oncology Group
- Conditions
- Thymoma, Thymic Carcinoma
- Interventions
- carboplatin, paclitaxel
- First posted
- 2003-01-27
- Last updated
- 2023-06-29
- Results first posted
- 2012-10-18
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Best Overall Response by RECIST Criteria (Version 1.0) | Assessed every 2 cycles (6 weeks) | Number of eligible, treated participants in each response category by RECIST criteria |
| Secondary | Duration of Response | assessed every 3 months for 2 years, then every 6 months for 3 years, then annually thereafter | Time from first satisfaction of response criteria to onset of disease progression, assessed using RECIST criteria |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Best Overall Response by RECIST Criteria (Version 1.0) | Assessed every 2 cycles (6 weeks) | Analysis population included all eligible participants who received at least 1 dose of the protocol treatment | Participants | NUMBER |
| SECONDARY | Duration of Response | assessed every 3 months for 2 years, then every 6 months for 3 years, then annually thereafter | Number of participants achieving a complete or partial response by RECIST criteria | Months | MEDIAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymoma | Complete Response | 3 | Participants | |
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymic Carcinoma | Complete Response | 0 | Participants | |
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymoma | Partial Response | 5 | Participants | |
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymic Carcinoma | Partial Response | 6 | Participants | |
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymoma | Stable Disease | 13 | Participants | |
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymic Carcinoma | Stable Disease | 8 | Participants | |
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymoma | Progression | 0 | Participants | |
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymic Carcinoma | Progression | 4 | Participants | |
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymoma | Unevaluable | 2 | Participants | |
| Best Overall Response by RECIST Criteria (Version 1.0) | Thymic Carcinoma | Unevaluable | 2 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Thymoma | 25 | |
| Overall Study | STARTED | Thymic Carcinoma | 21 | |
| Overall Study | COMPLETED | Thymoma | 24 | |
| Overall Study | COMPLETED | Thymic Carcinoma | 21 | |
| Overall Study | NOT COMPLETED | Thymoma | 1 | |
| Overall Study | NOT COMPLETED | Thymic Carcinoma | 0 |
Source ClinicalTrials.gov
Adverse events136
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Thymoma | 17 | 24 | |
| other | Anemia | Blood and lymphatic system disorders | Thymic Carcinoma | 19 | 21 | |
| other | Allergic Reaction | Immune system disorders | Thymoma | 0 | 24 | |
| other | Allergic Reaction | Immune system disorders | Thymic Carcinoma | 1 | 21 | |
| other | Leukopenia | Blood and lymphatic system disorders | Thymoma | 13 | 24 | |
| other | Leukopenia | Blood and lymphatic system disorders | Thymic Carcinoma | 12 | 21 | |
| other | Neutropenia | Blood and lymphatic system disorders | Thymoma | 15 | 24 | |
| other | Neutropenia | Blood and lymphatic system disorders | Thymic Carcinoma | 10 | 21 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Thymoma | 5 | 24 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Thymic Carcinoma | 9 | 21 |
1 to 10 of 136Source ClinicalTrials.gov
See all 136 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Thymoma | ||
| Total, all-cause mortality | Thymic Carcinoma | ||
| Total, other adverse events | Thymoma | 24 | 24 |
| Total, other adverse events | Thymic Carcinoma | 21 | 21 |
| Total, serious adverse events | Thymoma | 13 | 24 |
| Total, serious adverse events | Thymic Carcinoma | 14 | 21 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21502559 | RESULT |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA021115 | Eastern Cooperative Oncology Group Operations Office | COMIS, ROBERT L | FRONTIER SCI & TECHNOLOGY RSCH FDN, INC | NATIONAL CANCER INSTITUTE | 1985 to 2013 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Thymoma vs Thymic Carcinoma: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00010257
GET https://conductscience.org/api/trials/v1/NCT00010257/events?page=2